

Financial news for EPZM dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for EPZM dated on 2020-05-13: Epizyme To Present Data From Tazemetostat At ASCO May 29

Financial news for EPZM dated on 2020-05-05: Oppenheimer Maintains Perform on Epizyme, Raises Price Target to \$17

Financial news for EPZM dated on 2020-05-04: Epizyme: Q1 Earnings Insights

Financial news for EPZM dated on 2020-05-04: Epizyme Q1 EPS \$(0.51) Beats \$(0.74) Estimate, Sales \$1.354M Miss \$3.680M Estimate

Financial news for EPZM dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for EPZM dated on 2020-04-08: Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.

Financial news for EPZM dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for EPZM dated on 2020-04-01: Oppenheimer Downgrades Epizyme to Perform, Lowers Price Target to \$16

Financial news for EPZM dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for EPZM dated on 2020-03-04: Benzinga's Top Upgrades, Downgrades For March 4, 2020

Financial news for EPZM dated on 2020-03-04: Epizyme shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and a price target of \$33 per share.

Financial news for EPZM dated on 2020-03-04: Barclays Initiates Coverage On Epizyme with Overweight Rating, Announces \$33 Price Target

Financial news for EPZM dated on 2020-02-25: Epizyme shares are trading higher on a rebound after the stock dipped following the release of Q4 earnings on Monday. UPDATE: Shares have since reversed, now lower.

Financial news for EPZM dated on 2020-02-25: 77 Biggest Movers From Yesterday

Financial news for EPZM dated on 2020-02-24: 55 Stocks Moving In Monday's Mid-Day Session

Financial news for EPZM dated on 2020-02-24: Epizyme shares are trading lower following Q4 results. NOTE: Weakness may also be market related, as global equities are lower for the session amid coronavirus fears.

Financial news for EPZM dated on 2020-02-24: Epizyme Q4 EPS \$(0.59) Misses \$(0.5) Estimate, Sales \$4.294M Beat \$3.08M Estimate

Financial news for EPZM dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for EPZM dated on 2020-02-18: 76 Biggest Movers From Friday

Financial news for EPZM dated on 2020-02-14: Epizyme shares are trading higher after the company announced FDA accepted for filing the company's New Drug Application for the accelerated approval of TAZVERIK.

Financial news for EPZM dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for EPZM dated on 2020-02-14: Epizyme Reports FDA Acceptance Of New Drug Application For Filing With Priority Review For TAZVERIK For Treatment Of Follicular Lymphoma

Financial news for EPZM dated on 2020-02-10: Epizyme shares are trading higher after hearing the company's Tazemetostat has been added to the National Comprehensive Cancer Network Guidelines as a category 2A recommendation for the treatment of soft-tissue sarcoma.

Financial news for EPZM dated on 2020-02-10: Epizyme Shares Spike To Session High As Hearing Co.'s Tazemetostat Has Been Added To National Comprehensive Cancer Network Guideliness As Category 2A Recommendation For Treatment Of Soft-Tissue Sarcoma

Financial news for EPZM dated on 2020-01-27: Epizyme shares are trading lower in sympathy with the overall market as the Wuhan coronavirus continues to spread throughout the country, prompting travel bans in multiple Chinese cities. Reports say the death toll rose to 80 as of Sunday.

Financial news for EPZM dated on 2020-01-27: 70 Biggest Movers From Friday

Financial news for EPZM dated on 2020-01-26: The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes

Financial news for EPZM dated on 2020-01-24: Epizyme shares are trading lower despite the company receiving accelerated FDA approval for TAZVERIK. A Wedbush analysts noted a 'relatively low initial price point' for the drug.

Financial news for EPZM dated on 2020-01-24: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for EPZM dated on 2020-01-24: Epizyme Shares Down 9% Despite Accelerated FDA Approval For Its Epithelioid Sarcoma Treatment; Wedbush Analyst David Nierengarten Attributes Move To Potential 'Sell On The News' Response As Well Potential Lower-Than-Expected Pricing Of The Drug

Financial news for EPZM dated on 2020-01-24: Morgan Stanley Maintains Overweight on Epizyme, Raises Price Target to \$28

Financial news for EPZM dated on 2020-01-24: Epizyme shares are trading lower despite the company receiving accelerated FDA approval for TAZVERIK.

Financial news for EPZM dated on 2020-01-24: Wedbush Maintains Outperform on Epizyme, Raises Price Target to \$30

Financial news for EPZM dated on 2020-01-24: The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

Financial news for EPZM dated on 2020-01-24: Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval

Financial news for EPZM dated on 2020-01-23: Benzinga Pro's Top 5 Stocks To Watch For Thurs., Jan. 23, 2020: CODX, LUV, INTC, PAYC, EPZM

Financial news for EPZM dated on 2020-01-23: Epizyme shares are trading higher after Citigroup maintained its Buy rating on the stock and raised its price target from \$25 to \$35 per share.

Financial news for EPZM dated on 2020-01-23: Citigroup Maintains Buy on Epizyme, Raises Price Target to \$35

Financial news for EPZM dated on 2020-01-23: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

Financial news for EPZM dated on 2020-01-23: Watch Epizyme Shares Thurs. Amid PDUFA Date For Tazemetostat For Epithelioid Sarcoma

Financial news for EPZM dated on 2020-01-23: 36 Stocks Moving in Thursday's Pre-Market Session

Financial news for EPZM dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for EPZM dated on 2020-01-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for EPZM dated on 2020-01-20: The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings

Financial news for EPZM dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for EPZM dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment

Inflicts Pain On Durect Shares

Financial news for EPZM dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for EPZM dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for EPZM dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for EPZM dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for EPZM dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for EPZM dated on 2020-01-06: Epizyme Exercises its Option to Sell \$50M of Stock to Royalty Pharma

Financial news for EPZM dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for EPZM dated on 2020-01-01: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for EPZM dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for EPZM dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for EPZM dated on 2019-12-19: 64 Biggest Movers From Yesterday

Financial news for EPZM dated on 2019-12-18: Epizyme Reports Submission Of New Drug Application For Tazemetostat For Treatment Of Patients With Follicular Lymphoma

Financial news for EPZM dated on 2019-12-18: Epizyme shares are trading higher after the FDA advisory committee voted unanimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma.

Financial news for EPZM dated on 2019-12-18: Epizyme Shares Resume Trade

Financial news for EPZM dated on 2019-12-18: Epizyme Shares To Resume Trade At 2:30 p.m. EDT

Financial news for EPZM dated on 2019-12-18: Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

Financial news for EPZM dated on 2019-12-18: Hearing FDA AdCom Panel Votes 11-0 Benefits Of Epizyme's Tazemetostat Outweight Risks

Financial news for EPZM dated on 2019-12-18: FDA Votes Unanimously In Favor Of Epizyme's Tazemetostat

Financial news for EPZM dated on 2019-12-18: Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 18, 2019: UPS, MU, EPZM, SLDB, XXII

Financial news for EPZM dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for EPZM dated on 2019-12-18: UPDATE: Epizyme Shares Halted Ahead Of FDA Adcom

Financial news for EPZM dated on 2019-12-18: Epizyme Shares Halted, News Pending

Financial news for EPZM dated on 2019-12-15: The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week

Financial news for EPZM dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for EPZM dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for EPZM dated on 2019-12-09: 74 Biggest Movers From Friday

Financial news for EPZM dated on 2019-12-07: Epizyme Presents Updated Phase 2 Data Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma at ASH 2019

Financial news for EPZM dated on 2019-12-06: 55 Stocks Moving In Friday's Mid-Day Session

Financial news for EPZM dated on 2019-12-06: Stocks That Hit 52-Week Highs On Friday

Financial news for EPZM dated on 2019-12-06: Epizyme shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price action from \$12 to \$22 per share.

Financial news for EPZM dated on 2019-12-06: Benzinga's Top Upgrades, Downgrades For December 6, 2019

Financial news for EPZM dated on 2019-12-06: 10 Biggest Price Target Changes For Friday

Financial news for EPZM dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for EPZM dated on 2019-12-06: A Peek Into The Markets: US Stock Futures Up; Jobs Report In Focus

Financial news for EPZM dated on 2019-12-06: Morgan Stanley Upgrades Epizyme to Overweight, Raises Price Target to \$22

Financial news for EPZM dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for EPZM dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for EPZM dated on 2019-11-21: Stocks That Hit 52-Week Highs On Thursday

Financial news for EPZM dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for EPZM dated on 2019-11-18: RPI Finance Trust Reports 9.1% Share Stake In Epizyme Inc As Of November 6; RPI Finance Says It Acquired Epizyme Securities For Investment Purposes

Financial news for EPZM dated on 2019-11-06: 61 Biggest Movers From Yesterday

Financial news for EPZM dated on 2019-11-05: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EPZM dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for EPZM dated on 2019-11-04: Epizyme Establishes Agreements for Up to \$270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement

Financial news for EPZM dated on 2019-10-30: Epizyme Announces 'Positive' Pre-NDA Meeting For Tazemetostat For Follicular Lymphoma, Pipeline Updates And Third Quarter 2019 Results

Financial news for EPZM dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for EPZM dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for EPZM dated on 2019-08-09: Epizyme Sees Its Cash Runway Extending Into Q1'21

Financial news for EPZM dated on 2019-08-09: Epizyme Q2 EPS \$(0.53), Inline, Sales \$5.9M Beat \$1.75M Estimate

Financial news for EPZM dated on 2019-07-25: Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma

Financial news for EPZM dated on 2019-06-26: 51 Biggest Movers From Yesterday

Financial news for EPZM dated on 2019-06-24: 68 Biggest Movers From Friday

Financial news for EPZM dated on 2019-06-21: Epizyme Highlights Presentation Of Updated Data From Phase 2 Trial Of Tazemetostat In Patients With Relapsed Or Refractory Follicular Lymphoma; Data Showed 'Durable and Clinically Meaningful Responses'

Financial news for EPZM dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for EPZM dated on 2019-06-15: The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Financial news for EPZM dated on 2019-06-13: 50 Biggest Movers From Yesterday

Financial news for EPZM dated on 2019-06-12: 35 Stocks Moving In Wednesday's Mid-Day Session

Financial news for EPZM dated on 2019-06-03: Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma at #ASCO19; New Clinical Data Presented Today Included In Recently Submitted NDA to FDA

Financial news for EPZM dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for EPZM dated on 2019-05-30: Epizyme Highlights Submission Of New Drug Application To FDA For Tazemetostat For Treatment Of Patients With Epithelioid Sarcoma

Financial news for EPZM dated on 2019-05-06: A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 500 Points

Financial news for EPZM dated on 2019-05-06: Epizyme Says Has Cash Runway To Extend Into At Least Q1'21

Financial news for EPZM dated on 2019-05-06: Epizyme Q1 EPS \$(0.39) Beats \$(0.46) Estimate, Sales \$7.9M Beat \$2.16M Estimate

Financial news for EPZM dated on 2019-04-18: Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.

Financial news for EPZM dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for EPZM dated on 2019-03-07: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for EPZM dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for EPZM dated on 2019-03-07: Epizyme Prices 10M Share Common Stock Offering @\$11.50/Share

Financial news for EPZM dated on 2019-03-06: Epizyme Reports Offering Of Common Stock, Series A Preferred Shares, No Size Disclosed

Financial news for EPZM dated on 2019-03-01: Epizyme 8-K Shows Partial Clinical Hold On New Patient Enrollment For Studies Of Tazemetostat In France Has Been Lifted

Financial news for EPZM dated on 2019-02-27: 72 Biggest Movers From Yesterday

Financial news for EPZM dated on 2019-02-26: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EPZM dated on 2019-02-26: Epizyme shares are trading higher after the company beat Q4 EPS estimates.

Financial news for EPZM dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for EPZM dated on 2019-02-26: Epizyme Q4 EPS \$(0.29) Beats \$(0.48) Estimate

Financial news for EPZM dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for EPZM dated on 2019-01-07: Shares of several cancer therapeutics companies are trading higher after Loxo Oncology received an acquisition offer from Eli Lilly.

Financial news for EPZM dated on 2019-01-07: Epizyme shares are trading higher after the Leerink Swann Upgraded the company's stock from Market Perform to Outperform.

Financial news for EPZM dated on 2019-01-07: Leerink Swann Upgrades Epizyme to Outperform

Financial news for EPZM dated on 2019-01-07: 21 Stocks Moving In Monday's Pre-Market Session

Financial news for EPZM dated on 2019-01-07: 58 Biggest Movers From Friday

Financial news for EPZM dated on 2019-01-04: Epizyme Shares Spike To Session High Over \$7.50 Level Over Last Few Mins., Now Over \$8 Level, Up 34.3%

Financial news for EPZM dated on 2019-01-04: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for EPZM dated on 2019-01-04: Epizyme shares are trading higher after the company announced a registration path for Tazemetostat, provided pipeline updates, and stated FY19 guidance.

Financial news for EPZM dated on 2019-01-04: UPDATE: Epizyme Sees Capital Runway Into Q2'20

Financial news for EPZM dated on 2019-01-04: Epizyme Outlines Registration Path For Tazemetostat; Offers Pipeline, FY19 Guidance

Financial news for EPZM dated on 2019-01-04: 58 Biggest Movers From Yesterday

Financial news for EPZM dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for EPZM dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for EPZM dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for EPZM dated on 2018-12-18: Epizyme Earns \$8M Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For PRMT1 Inhibitor

Financial news for EPZM dated on 2018-12-17: Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Financial news for EPZM dated on 2018-12-14: Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018

Financial news for EPZM dated on 2018-12-14: The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Financial news for EPZM dated on 2018-12-13: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Financial news for EPZM dated on 2018-12-12: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 11, 2018

Financial news for EPZM dated on 2018-12-10: Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Financial news for EPZM dated on 2018-12-07: The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Financial news for EPZM dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for EPZM dated on 2018-11-23: Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018

Financial news for EPZM dated on 2018-11-21: Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018

Financial news for EPZM dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for EPZM dated on 2018-11-15: Epizyme To Host Conference Call Thurs., Nov. 15, 2018 At 8:30 a.m. EST To Discuss Corporate Updates

Financial news for EPZM dated on 2018-11-15: UPDATE: Epizyme Will Be Eligible To Receive Upfront Payment Of \$15M Plus Added \$5M in Research Funding In 2019; Is Eligible To Receive \$280M+ In Added Payments For R&D, Regulatory, Commercial Milestones

Financial news for EPZM dated on 2018-11-15: Epizyme Reports Global Collaboration With Boehringer Ingelheim To Develop Novel Epigenetic Oncology Therapies

Financial news for EPZM dated on 2018-11-02: Epizyme Q3 EPS \$(0.54) Beats \$(0.61) Estimate

Financial news for EPZM dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for EPZM dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for EPZM dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for EPZM dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for EPZM dated on 2018-10-22: Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report

Financial news for EPZM dated on 2018-10-22: REMINDER: ESMO 2018 Event Continues Today, Clinical Updates Presented Today Include: CytomX Therapeutics, Mirati Therapeutics, Merck, NuCana, Protagonist Therapeutics, SELLAS Life Sciences, Epizyme, Kura Oncology, Intra-Cellular Therapies, and AVEO Pharma

Financial news for EPZM dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for EPZM dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for EPZM dated on 2018-10-04: 55 Biggest Movers From Yesterday

Financial news for EPZM dated on 2018-10-03: 43 Stocks Moving In Wednesday's Mid-Day Session

Financial news for EPZM dated on 2018-10-03: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for EPZM dated on 2018-10-03: The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

Financial news for EPZM dated on 2018-10-03: 8 Stocks To Watch For October 3, 2018

Financial news for EPZM dated on 2018-10-03: Epizyme Prices 8.3M Share Public Offering of Common Stock @\$9/Share

Financial news for EPZM dated on 2018-10-02: 7 Stocks Moving In Tuesday's After-Hours Session

Financial news for EPZM dated on 2018-10-02: Epizyme Reports Offering Of Common Stock, No Size Disclosed

Financial news for EPZM dated on 2018-09-25: Leerink Swann Initiates Coverage On Epizyme with Market Perform Rating, Announces \$11 Price Target

Financial news for EPZM dated on 2018-09-24: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for EPZM dated on 2018-09-24: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for EPZM dated on 2018-09-24: Epizyme Announces FDA Lifts Partial Clinical Hold on Tazemetostat Clinical Program

Financial news for EPZM dated on 2018-09-07: Morgan Stanley Reinstates Equal-Weight

on Epizyme, Announces \$12 Price Target

Financial news for EPZM dated on 2018-09-05: Court Filing Shows A US Judge Has Blocked State Of Texas's Fetal Tissue Burial Law

Financial news for EPZM dated on 2018-08-03: Stocks Which Set New 52-Week Low Yesterday, August 2nd

Financial news for EPZM dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for EPZM dated on 2018-08-03: 75 Biggest Movers From Yesterday

Financial news for EPZM dated on 2018-08-02: 65 Stocks Moving In Thursday's Mid-Day Session

Financial news for EPZM dated on 2018-08-02: Mid-Day Market Update: Cross Country Healthcare Drops After Downbeat Q2 Results; InnSuites Hospitality Trust Shares Climb

Financial news for EPZM dated on 2018-08-02: Epizyme shares are trading 15% lower after the company announced mixed quarterly earnings. The company also announced it has terminated development of tazemetostat for large B-cell lymphoma due to lack of efficacy.

Financial news for EPZM dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for EPZM dated on 2018-08-02: Epizyme Q2 EPS \$(0.42) Beats \$(0.51) Estimate

Financial news for EPZM dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for EPZM dated on 2018-07-05: 45 Biggest Movers From Tuesday

Financial news for EPZM dated on 2018-07-03: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EPZM dated on 2018-07-03: Mid-Day Market Update: U.S. Stocks Turn Negative; Anavex Life Sciences Shares Spike Higher

Financial news for EPZM dated on 2018-07-03: Mid-Morning Market Update: Markets Open Higher; Acuity Brands Beats Q3 Expectations

Financial news for EPZM dated on 2018-07-03: 6 Biggest Price Target Changes For Tuesday

Financial news for EPZM dated on 2018-07-03: Benzinga's Top Upgrades, Downgrades For July 3, 2018

Financial news for EPZM dated on 2018-07-03: Leerink Swann Downgrades Epizyme to Market Perform

Financial news for EPZM dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for EPZM dated on 2018-06-15: Epizyme Reports Positive Updated Interim Data From Phase 2 Study Of Tazemetostat In Patients With Relapsed Or Refractory Follicular Lymphoma At Congress Of The European Hematology Association (EHA)

Financial news for EPZM dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for EPZM dated on 2018-06-03: Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at #ASCO2018

Financial news for EPZM dated on 2018-05-18: 5 Biggest Price Target Changes For Friday

Financial news for EPZM dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for EPZM dated on 2018-05-08: Epizyme Says Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient To Fund Planned Operations Into Q3'19

Financial news for EPZM dated on 2018-05-08: Epizyme Q1 EPS \$(0.49) Beats \$(0.54) Estimate



Financial news for EPZM dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for EPZM dated on 2018-04-25: 38 Biggest Movers From Yesterday

Financial news for EPZM dated on 2018-04-24: Mid-Afternoon Market Update: Dow Falls Over 500 Points; Santander Consumer USA Shares Gain On Earnings Beat

Financial news for EPZM dated on 2018-04-24: 'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish

Financial news for EPZM dated on 2018-04-24: 32 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EPZM dated on 2018-04-24: Mid-Day Market Update: Sanmina Surges Following Q2 Beat; Valeritas Shares Slide

Financial news for EPZM dated on 2018-04-24: Mid-Morning Market Update: Markets Mostly Flat; Coca-Cola Beats Q1 Views

Financial news for EPZM dated on 2018-04-24: Epizyme Shares Drop After Partial Clinical Hold Placed On Lead Cancer Drug

Financial news for EPZM dated on 2018-04-23: Epizyme Shares Down 17.3% After Hours Following Announcement Of Temporary Clinical Hold On Patient Enrollment For Tazemetostat; Co. Must Confirm Alignment With FDA To Resume Enrollment

Financial news for EPZM dated on 2018-04-23: Epizyme Shares To Resume Trade At 5:15 p.m. EDT

Financial news for EPZM dated on 2018-04-23: Epizyme Announces Temporary Clinical Hold On Patient Enrollment For Tazemetostat, Will Need To Confirm Alignment With FDA To Resume Enrollment

Financial news for EPZM dated on 2018-04-23: Epizyme Shares Halted News Pending

Financial news for EPZM dated on 2018-04-05: Epizyme Files For Potential Mixed Shelf Offering, Size Not Disclosed

Financial news for EPZM dated on 2018-03-13: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EPZM dated on 2018-03-13: Epizyme Reports Q4 EPS \$(0.52) vs \$(0.57) Est., No Sales

Financial news for EPZM dated on 2018-03-11: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for EPZM dated on 2018-01-11: 36 Biggest Movers From Yesterday

Financial news for EPZM dated on 2018-01-10: ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax

Financial news for EPZM dated on 2018-01-10: Epizyme Shares Up 16.4%; Earlier Morgan Stanley Initiated Stock At Overweight, Saying Co. Has 'Blockbuster' Drug In The Making, Believes Share Price Doesn't Reflect Tazemetostat's Potential

Financial news for EPZM dated on 2018-01-10: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for EPZM dated on 2018-01-10: Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making

Financial news for EPZM dated on 2018-01-10: Benzinga's Top Upgrades, Downgrades For January 10, 2018

Financial news for EPZM dated on 2018-01-10: Morgan Stanley Initiates Coverage On Epizyme with Overweight Rating, Announces \$20.00 Price Target

Financial news for EPZM dated on 2017-12-11: Epizyme Introduces Next Drug Candidate, EZM266, The First of Three New Compounds to be Named as Part of Epizyme's Vision 2020

Financial news for EPZM dated on 2017-12-10: Epizyme Presents New Biomarker Data on Tazemetostat at #ASH2017

Financial news for EPZM dated on 2017-11-03: 66 Biggest Movers From Yesterday

Financial news for EPZM dated on 2017-11-02: 52 Stocks Moving In Thursday's Mid-Day

## Session

Financial news for EPZM dated on 2017-11-02: Benzinga's Top Upgrades, Downgrades For November 2, 2017

Financial news for EPZM dated on 2017-11-02: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for EPZM dated on 2017-11-02: RBC Capital Downgrades Epizyme to Sector Perform

Financial news for EPZM dated on 2017-11-01: Epizyme Q3 EPS \$(0.63) vs \$(0.65) Est., No Sales

Financial news for EPZM dated on 2017-10-27: Epizyme Offers Data From Phase 1 Trial Of Tazemetostat In Children With Relapsed, Refractory INI-1Negative Solid Tumors: 'First presentation of pediatric dose escalation in tazemetostat, showing favorable safety, tolerability'

Financial news for EPZM dated on 2017-10-02: Epizyme Shares Make New 52-Week High Of \$20.44, Now Up 6.3% At \$20.25

Financial news for EPZM dated on 2017-09-20: Benzinga's Top Upgrades, Downgrades For September 20, 2017

Financial news for EPZM dated on 2017-09-20: Jefferies Initiates Coverage On Epizyme with Buy Rating, Announces \$23.00 Price Target

Financial news for EPZM dated on 2017-09-14: 12 Biggest Mid-Day Losers For Thursday

Financial news for EPZM dated on 2017-09-14: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for EPZM dated on 2017-09-14: Epizyme Prices 9.18M Share Offering at \$15.25/Share

Financial news for EPZM dated on 2017-09-14: 5 Stocks To Watch For September 14, 2017

Financial news for EPZM dated on 2017-09-13: Epizyme Announces \$120M Share Offering Common Stock

Financial news for EPZM dated on 2017-08-15: Epizyme CFO to Step Down to Pursue Other Opportunities

Financial news for EPZM dated on 2017-08-04: 20 Biggest Mid-Day Gainers For Friday

Financial news for EPZM dated on 2017-08-04: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for EPZM dated on 2017-08-04: Epizyme Reports Q2 EPS \$(0.48) vs \$(0.55) Est., Sales \$10M vs \$2.83M Est.

Financial news for EPZM dated on 2017-07-24: Epizyme Reports Tazemetostat to be Evaluated in NCI's Recently Initiated NCI-COG Pediatric MATCH Trial

Financial news for EPZM dated on 2017-06-28: Epizyme Chief Scientific Officer Robert Copeland to Retire Effective June 30, 2017 -8-K

Financial news for EPZM dated on 2017-06-26: Epizyme To Collaborate with Genetech for Collaboration on TECENTRIQ

Financial news for EPZM dated on 2017-06-21: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for EPZM dated on 2017-06-21: Epizyme's Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma

Financial news for EPZM dated on 2017-06-18: Epizyme Receives FDA Orphan Designation for Tazemetostat

Financial news for EPZM dated on 2017-06-14: 10 Biggest Mid-Day Losers For Wednesday

Financial news for EPZM dated on 2017-06-14: Epizyme Shares Quiet Here As Traders Circulating Positive Comments From Leerink

Financial news for EPZM dated on 2017-06-14: UPDATE: Epizyme Says Interim Data For Tazemetostat Showed Treatment Resulted In Clinically Meaningful Benefit In Patients With FL

Financial news for EPZM dated on 2017-06-14: Epizyme Reports Interim Data From Phase

2 Trial For Tazemetostat In Relapsed, Refractory Follicular Lymphoma, DLBCL Patients

Financial news for EPZM dated on 2017-06-05: Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data

Financial news for EPZM dated on 2017-05-18: Epizyme Announces Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Data to be Presented at ASCO

Financial news for EPZM dated on 2017-05-08: Epizyme Q1 EPS \$(0.56) vs \$(0.63) Est, No Sales

Financial news for EPZM dated on 2017-05-04: Epizyme Reports Earned \$10M Milestone Payment from GlaxoSmithKline Related to Initiation of GLP Toxicology Studies with Novel Methytransferase Inhibitor

Financial news for EPZM dated on 2017-04-25: 20 Biggest Mid-Day Gainers For Tuesday

Financial news for EPZM dated on 2017-04-25: Epizyme Granted Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML

Financial news for EPZM dated on 2017-04-13: Oppenheimer Initiates Coverage On Epizyme with Outperform Rating, Announces \$26.00 Price Target

Financial news for EPZM dated on 2017-03-09: Epizyme Says Pres of Research, Chief Scientific Officer, Robert Copeland, to Retire

Financial news for EPZM dated on 2017-03-09: Epizyme Expects Cash, Cash Equivalents, Marketable Securities of \$242.2M to be Sufficient to Fund Co.'s Planned Operations Through At Least Q3'18

Financial news for EPZM dated on 2017-03-09: Epizyme Reports Q4 Loss \$35M vs \$22M Loss in Same Qtr. Last Year, Collaboration Sales \$500K vs \$600K YoY

Financial news for EPZM dated on 2017-01-19: Epizyme Receives Written Positive Response From FDA Allowing Enrollment Of Patients With Follicular Lymphoma

Financial news for EPZM dated on 2016-11-28: Good And Bad News from Epizyme; Wedbush Analyst Weighs In

Financial news for EPZM dated on 2016-11-28: A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street

Financial news for EPZM dated on 2016-11-28: Epizyme Gets Fast Track Designation for Tazemetostat

Financial news for EPZM dated on 2016-11-03: Epizyme Q3 EPS \$(0.42) vs \$(0.60) Est, Revenue \$6.6K vs \$470K

Financial news for EPZM dated on 2016-10-31: Epizyme to Expand Clinical Programs with National Cancer Institute

Financial news for EPZM dated on 2016-10-31: Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute

Financial news for EPZM dated on 2016-09-15: Epizyme Gets \$6M Milestone Payment from GlaxoSmithKline

Financial news for EPZM dated on 2016-08-11: Epizyme Reports Dosing of First Patient in Phase 2 Study Evaluating Tazemetostat in Mesothelioma

Financial news for EPZM dated on 2016-08-08: Mid-Afternoon Market Update: Crude Oil Up 3.5%; Ceragon Shares Drop Following Q2 Results

Financial news for EPZM dated on 2016-08-08: 12 Biggest Mid-Day Losers For Monday

Financial news for EPZM dated on 2016-08-08: Mid-Day Market Update: Mattress Firm Jumps Following Buyout; Digital Ally Shares Slide

Financial news for EPZM dated on 2016-08-08: Epizyme Q2 EPS (\$0.49) vs (\$0.52) est, Revenue \$473K vs \$880K est

Financial news for EPZM dated on 2016-06-22: Epizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq for Treatment of Non-Hodgkin Lymphoma

Financial news for EPZM dated on 2016-06-20: 6 Biggest Mid-Day Losers For Monday

Financial news for EPZM dated on 2016-06-20: Mid-Day Market Update: Crude Oil Rises

## 2.5%; Epizyme Shares Drop

Financial news for EPZM dated on 2016-06-20: Mid-Morning Market Update: Markets Open Higher; Icahn Enterprises Raises Offer For Federal Mogul

Financial news for EPZM dated on 2016-06-19: Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting

Financial news for EPZM dated on 2016-05-09: Epizyme Q1 EPS (\$0.41) vs (\$0.53) est, Revenue \$472K vs \$900K est

Financial news for EPZM dated on 2016-05-09: Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP

Financial news for EPZM dated on 2016-05-06: Epizyme Names Matthew Ros COO

Financial news for EPZM dated on 2016-05-04: Epizyme Says FDA Accepts IND for Its Tazemetostat In Mesothelioma

Financial news for EPZM dated on 2016-05-04: Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma

Financial news for EPZM dated on 2016-04-25: Epizyme Names Susan Graf Chief Business Officer

Financial news for EPZM dated on 2016-04-18: Epizyme Shows Data From 13-Patient Study Showing Tazemetostat Can Be Administered With or Without Food, Only A Weak Inducer Of CYP3A-Mediated Metabolism

Financial news for EPZM dated on 2016-04-05: Citigroup Initiates Coverage on Epizyme at Buy, Announces \$17.00 PT

Financial news for EPZM dated on 2016-03-23: Why These 5 Stocks Are Moving After Hours

Financial news for EPZM dated on 2016-03-14: Benzinga's Top Upgrades

Financial news for EPZM dated on 2016-03-14: H.C. Wainwright Upgrades Epizyme to Buy, Raises PT to \$25.00

Financial news for EPZM dated on 2016-03-09: Epizyme Q4 Earnings Conference Call: Full Transcript

Financial news for EPZM dated on 2016-03-09: Epizyme Q4 EPS (\$0.53) vs (\$0.65) est, Revenue \$555K vs \$570K est

Financial news for EPZM dated on 2016-03-09: Epizyme Says Focused on Accelerating Development of Tazemetostat

Financial news for EPZM dated on 2016-03-09: Epizyme Gives Pipeline Objectives Through 2020

Financial news for EPZM dated on 2016-03-09: Earnings Scheduled For March 9, 2016

Financial news for EPZM dated on 2016-02-16: Patrick Lee Reports 6.38% Passive Stake in Epizyme in 13G

Financial news for EPZM dated on 2016-02-08: Epizyme Reports FDA Grants ODD For Tazemetostat For Treatment Of Malignant Rhabdoid Tumors

Financial news for EPZM dated on 2016-01-07: Here's Why There's Been A Rush Of Biotech Offerings

Financial news for EPZM dated on 2016-01-07: Mid-Morning Market Update: Markets Open Lower; KB Home Misses Q4 Views

Financial news for EPZM dated on 2016-01-07: Benzinga's Top #PreMarket Losers

Financial news for EPZM dated on 2016-01-07: Epizyme Prices ~13.33M Share Offering @ \$9.00/Share

Financial news for EPZM dated on 2016-01-06: Mid-Afternoon Market Update: Dow Slides Over 300 Points; Otonomy Shares Tumble Following Public Offering Of Stock

Financial news for EPZM dated on 2016-01-06: Mid-Day Market Update: Crude Oil Falls Over 4%; Conatus Pharmaceuticals Shares Rise Following Positive Results In Phase 2 Study

Financial news for EPZM dated on 2016-01-06: Mid-Morning Market Update: Markets Open

Lower; Monsanto Posts Narrower-Than-Expected Loss

Financial news for EPZM dated on 2016-01-05: Notable Buy-Side Biotech Analyst Brad Loncar Notes Heavy Biotech Offerings Taking Place After Hours In Tweet

Financial news for EPZM dated on 2016-01-05: Epizyme Reports Offering of \$120M Shares

Financial news for EPZM dated on 2015-12-30: Epizyme Reports First Patient Dosed in Clinical Program Evaluating Tazemetostat; Says Now Enrolling Adults in Phase 2 Study, Pediatric Patients in Escalation Study

Financial news for EPZM dated on 2015-12-29: 10 Biotechs Short Sellers Are Betting Against

Financial news for EPZM dated on 2015-12-29: JMP Securities Sees Epizyme's Tazemetostat Acceptance Easing Investor Concern, Views Step As Noteworthy For Company Going Forward

Financial news for EPZM dated on 2015-12-28: Epizyme Reports FDA Acceptance of INDA for Tazemetostat in Diffuse Large B-Cell Lymphoma

Financial news for EPZM dated on 2015-12-22: SunTrust Robinson Humphrey Initiates Coverage on Epizyme at Buy, Announces \$21.00 PT

Financial news for EPZM dated on 2015-12-07: Epizyme Reports Updated Data from Ongoing Phase 1 Study of Tazemetostat Showing Objective, Durable Responses in Relapsed, Refractory NHL

Financial news for EPZM dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for EPZM dated on 2015-09-26: Epizyme Updated Tazemetostat Phase 1 Data Show Clinical Activity in a Broader Range of Adults With IN11-Negative and SMARCA4-Negative Solid Tumors

Financial news for EPZM dated on 2015-08-24: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with IN11-Negative Tumors or Synovial Sarcoma

Financial news for EPZM dated on 2015-08-20: 10 Biotech Stocks With Catalysts Coming Soon

Financial news for EPZM dated on 2015-07-20: Benzinga's Top Downgrades

Financial news for EPZM dated on 2015-07-20: H.C. Wainwright Destroys Epizyme Price Target, Sees 'No Material Value Drivers'

Financial news for EPZM dated on 2015-07-20: H.C. Wainwright Downgrades Epizyme to Neutral, Lowers PT to \$22.00

Financial news for EPZM dated on 2015-07-09: Epizyme Doses First Patient in Five-Arm Phase 2 Study for First-in-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma

Financial news for EPZM dated on 2015-07-09: Epizyme Reports Extension of Celgene Research Collab, Will Receive \$10M Fee Payment, Up to \$610M in Potential Milestones

Financial news for EPZM dated on 2015-07-06: Benzinga's Top Initiations

Financial news for EPZM dated on 2015-07-06: RBC Capital Initiates Epizyme With Outperform

Financial news for EPZM dated on 2015-07-06: RBC Capital Initiates Coverage on Epizyme at Outperform, Announces \$40.00 PT

Financial news for EPZM dated on 2015-06-29: Epizyme to Show Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat at the European Cancer Congress

Financial news for EPZM dated on 2015-06-23: Tuesday's Mid-Day Movers: Ambarella Retaliates; Sonic, BlackBerry Hit

Financial news for EPZM dated on 2015-06-23: Watch These 10 After-Hours Movers Today

Financial news for EPZM dated on 2015-06-22: Mid-Afternoon Market Update: Williams Surges Following Bid from ETE; Ambarella Shares Slide

Financial news for EPZM dated on 2015-06-22: Monday's Mid-Day Movers: Williams Companies, GoPro, Ambarella And More

Financial news for EPZM dated on 2015-06-22: Mid-Day Market Update: Martha Stewart Living Omnimedia Drops After Sequential Buyout Deal; CIGNA Shares Gain

Financial news for EPZM dated on 2015-06-22: Benzinga's Volume Movers

Financial news for EPZM dated on 2015-06-22: Mid-Morning Market Update: Markets Open Higher; Williams Companies Rejects Energy Transfer Equity Buyout Offer

Financial news for EPZM dated on 2015-06-22: Morning Market Gainers

Financial news for EPZM dated on 2015-06-20: Epizyme Reports Positive Data from Ongoing Phase 1 Study of Tazemetostat in Relapsed or Refractory NHL

Financial news for EPZM dated on 2015-04-28: Epizyme Reports Q1 EPS -\$1.75 Vs Est -\$0.99 May Not Compare

Financial news for EPZM dated on 2015-04-20: Epizyme Reports Preclinical Research Providing Deeper Understanding of Multiple Cancer Targets

Financial news for EPZM dated on 2015-04-20: Epizyme Will Present Updated Data from Ongoing Phase 1 Dose Escalation Trial of EZH2 Inhibitor EPZ-6438 at International Conference on Malignant Lymphoma

Financial news for EPZM dated on 2015-04-07: Regulus Therapeutics, Healthcare Stocks Are Big Movers In Tuesday's After Hours Trading

Financial news for EPZM dated on 2015-03-18: Epizyme Prices 6M Share Offering @\$20.75/Share

Financial news for EPZM dated on 2015-03-16: Epizyme Announces Proposed Public Offering of Common Stock, 4.75M

Financial news for EPZM dated on 2015-03-12: Morning Market Losers

Financial news for EPZM dated on 2015-03-12: Epizyme Q4 EPS -\$0.44 vs -\$0.53 est

Financial news for EPZM dated on 2015-03-03: Epizyme Announces Presentation of Data from Phase 1 Study of EZH2 Inhibitor EPZ-6438 (E7438)

Financial news for EPZM dated on 2015-02-03: Epizyme Appoints Andrew Singer as Chief Financial Officer

Financial news for EPZM dated on 2015-01-06: Primecap Exceeds 5% Threshold In Shutterfly, 3 Other Companies

Financial news for EPZM dated on 2015-01-06: From Amended 13G: Primecap Reports Increased Stake In Epizyme Now 12.04%

Financial news for EPZM dated on 2014-12-08: Epizyme Announces DOT1L Inhibitor EPZ-5676 Shows Clinical, Biological Activity in Adult Patients with Acute Leukemias; Separately Reports PRMT5 Inhibitor Showed In Vitro, In Vivo Activity

Financial news for EPZM dated on 2014-11-20: Mid-Day Gainers From November 20: Kirkland's, Americas Car-Mart, Cyberonics, Epizyme, Dillard's, Best Buy

Financial news for EPZM dated on 2014-11-06: Midday Losers From November 6: Qualcomm, Genworth Financial, Epizyme, Nationstar Mortgage

Financial news for EPZM dated on 2014-11-06: Morning Market Losers

Financial news for EPZM dated on 2014-11-06: Epizyme Reports Q3 EPS of \$(0.58) vs \$(0.55) Est; Revenue of \$8.18M vs \$6.93M Est

Financial news for EPZM dated on 2014-10-27: Epizyme Announces Departure of Chief Medical Officer Eric Hedrick

Financial news for EPZM dated on 2014-10-23: Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors

Financial news for EPZM dated on 2014-10-17: Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438)

Financial news for EPZM dated on 2014-10-10: Epizyme Announces Clinical And Pre-Clinical Data To Be Featured In Oral And Poster Presentations At American Society Of Hematology (ASH) Annual Meeting

Financial news for EPZM dated on 2014-09-12: UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play

Financial news for EPZM dated on 2014-09-12: Benzinga's Top Initiations

Financial news for EPZM dated on 2014-09-12: Mizuho Securities Initiates Epizyme With Buy

Financial news for EPZM dated on 2014-09-12: CORRECTION: Mizuho Securities Initiates Coverage on Epizyme at Buy, Announces \$35.00 PT

Financial news for EPZM dated on 2014-09-12: Mizuho Securities Initiates Coverage on Epizyme at Buy, Announces \$35.00 PT

Financial news for EPZM dated on 2014-09-02: Epizyme Announces Resignation Of President & CFO Jason Rhodes

Financial news for EPZM dated on 2014-09-02: Epizyme, Inc. Announces Resignation Of President And CFO Jason Rhodes

Financial news for EPZM dated on 2014-08-13: Epizyme Reports Q2 EPS of \$(0.40) vs \$(0.50) Est

Financial news for EPZM dated on 2014-08-12: Epizyme Offers Pre-Clinical Data, Early Clinical Observations from EPZ-6438 Trial, Maximum Tolerated Dose Not Reached, Evidence of Target Inhibition Observed

Financial news for EPZM dated on 2014-07-15: UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics

Financial news for EPZM dated on 2014-06-12: Epizyme Shares Quiet Following S-3 Filing Showing Registration for \$200M Mixed Securities Shelf

Financial news for EPZM dated on 2014-05-13: Epizyme Reports Q1 EPS of \$(0.22) vs \$(0.47) Est; Revenue of \$13.40M vs \$8.48M Est

Financial news for EPZM dated on 2014-04-22: Epizyme Reports Has Achieved Lead Candidate Milestone for Third Target in GSK Collab, Receives \$4M in Milestone, License Payments

Financial news for EPZM dated on 2014-04-08: Epizyme Wins Patent Covering Diagnosis, Treatment of Cancers with EZH2 Mutation

Financial news for EPZM dated on 2014-02-27: Epizyme Reports Q4 EPS of \$0.52 vs \$(0.22) Est; Revenue of \$15.90M vs \$15.63M Est

Financial news for EPZM dated on 2014-02-21: Epizyme Announces Publication Shows Positive Preclinical Data for EPZ-6438 in Genetically Non-Hodgkin Lymphoma

Financial news for EPZM dated on 2014-02-05: Epizyme Announces Pricing of Public Offering of Common Stock at \$29.25 per Share

Financial news for EPZM dated on 2014-02-03: Epizyme Offers 4.192M Shares of Common Stock at Proposed Maximum Offering Price of \$144.5M

Financial news for EPZM dated on 2014-01-07: Market Wrap For January 7: Markets Reverse 3-Day Slump

Financial news for EPZM dated on 2014-01-07: Mid-Morning Market Update: Markets Open Higher; IHS Profit Beats Estimates

Financial news for EPZM dated on 2014-01-07: Benzinga's Volume Movers

Financial news for EPZM dated on 2014-01-07: Morning Market Movers

Financial news for EPZM dated on 2013-11-15: Benzinga Weekly Preview: PMI Data In Focus

Financial news for EPZM dated on 2013-11-15: UPDATE: Citigroup Reiterates on Epizyme Awaiting Further Clarity

Financial news for EPZM dated on 2013-11-15: Citigroup Maintains Buy on Epizyme, Lowers PT to \$32.00

Financial news for EPZM dated on 2013-10-22: Epizyme Reports Q3 EPS of \$(0.34) vs \$(0.30) Est; Revenue of \$8.44M vs \$9.50M Est

Financial news for EPZM dated on 2013-08-12: UPDATE: Epizyme Leukemia Drug Receives FDA Orphan Drug Designation, Not Yet Approved

Financial news for EPZM dated on 2013-08-12: Epizyme Leukemia Treatment Gets Orphan

Drug Status From FDA - Bloomberg

Financial news for EPZM dated on 2013-07-31: Epizyme Reports Q2 EPS of \$(0.25) Which May Not Compare \$(0.36) Est; Revenue of \$14.80M Which May Not Compare \$13.40M Est

Financial news for EPZM dated on 2013-07-09: Market Wrap for Tuesday, July 9: Major Averages Closing in on Previous Highs

Financial news for EPZM dated on 2013-07-03: Epizyme, Inc. Appoints Jason P. Rhodes President

Financial news for EPZM dated on 2013-07-01: Epizyme, Inc. Added to Russell 2000(r) Index

Financial news for EPZM dated on 2013-06-27: UPDATE: Wedbush Initiates Epizyme at Outperform on Therapeutics Targeting HMTs

Financial news for EPZM dated on 2013-06-27: Wedbush Initiates Coverage on Epizyme at Outperform, Announces \$37.00 PT

Financial news for EPZM dated on 2013-06-26: Epizyme, Inc. Publishes Data Demonstrating EPZ-5676 as Potent, Selective Inhibitor of DOT1L for Genetically Defined Acute Leukemias

Financial news for EPZM dated on 2013-06-25: JMP Securities Initiates Coverage on Epizyme at Outperform, Announces \$40.00 PT

Financial news for EPZM dated on 2013-06-25: Leerink Swann Initiates Coverage on Epizyme at Outperform

Financial news for EPZM dated on 2013-06-25: Benzinga's Top Initiations

Financial news for EPZM dated on 2013-06-25: Citigroup Initiates Coverage on Epizyme at Buy, Announces \$32.00 PT

Financial news for EPZM dated on 2013-06-12: EXCLUSIVE: OTC Markets CEO Answers the Question: 'Is it Wise to Go Public?'

Financial news for EPZM dated on 2013-06-05: Afternoon Market Losers

Financial news for EPZM dated on 2013-05-31: Shares of Epizyme Open for Trade at \$20 After Pricing at \$15/Share

Financial news for EPZM dated on 2013-05-31: Epizyme Shares to Open for Trade at 10:20AM EDT, Priced 5.14M Shares at \$15/Share

Financial news for EPZM dated on 2013-05-13: Epizyme Files IPO for 4.285M Shares